This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endocyte Announces Presentations At The 244th American Chemical Society Meeting & Exposition

WEST LAFAYETTE, Ind., Aug. 14, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that three posters will be presented by Endocyte scientists at the 244 th American Chemical Society (ACS) Meeting & Exposition to be held in Philadelphia, Aug. 19 – 23, 2012.

"Positive clinical data have already demonstrated the potential of Endocyte's highly versatile modular platform to develop SMDCs," said Iontcho Vlahov, Ph.D., vice president of discovery chemistry. "At this ACS meeting the focus of our first presentation is centered on a proprietary, large scale synthesis of a novel derivative of Tubulysin B, a super-potent chemotherapeutic agent. The advantage of this 'tailored' molecule for conjugation with our novel guidance system is demonstrated as well. Our second presentation reveals the design of dimer war heads, based on the powerful DNA-cross-linking drug Mitomycin C, and the third presentation details newly discovered regio-selectivities for conjugation to targeting ligands of the anti-cancer drugs Etoposide and Mithramycin." 

Presentations are as follows:

Abstract #:  42
Title:  "Regio-selective activation of Mithramycin and Etoposide for synthesis of their folate conjugates"
When:  Sunday, Aug. 19, 7 p.m. – 9 p.m. EDT
Session ID:  General Poster Session
Location:  Pennsylvania Convention Center, Hall D
   
Abstract #:  62
Title:  "Design and Synthesis of Novel bis-Mitomycins and Their Folate Conjugates for Targeted Cancer Therapies"
When:  Sunday, Aug. 19, 7 p.m. – 9 p.m. EDT
Session ID:  General Poster Session
Location:  Pennsylvania Convention Center, Hall D
   
Abstract #:  304
Title:  "Efficient Synthesis of an Activated Tubulysin B Derivative for Ligand Targeting"
When:  Wednesday, Aug. 22, 7 p.m. – 10 p.m. EDT
Session ID:  General Poster Session
Location:  Pennsylvania Convention Center, Grand Ballroom

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,272.49 -13.25 -0.07%
S&P 500 2,130.19 -0.63 -0.03%
NASDAQ 5,097.9520 +7.1580 0.14%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs